Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,065.00GBp
24 Nov 2017
Change (% chg)

-9.00 (-0.84%)
Prev Close
1,074.00
Open
1,078.00
Day's High
1,079.00
Day's Low
1,060.00
Volume
114,736
Avg. Vol
985,094
52-wk High
2,346.00
52-wk Low
906.50

Select another date:

Tue, Nov 14 2017

BRIEF-Hikma Pharmaceuticals acquires six products from Boehringer Ingelheim GmbH

* ‍HIKMA ACQUIRES PRODUCTS IN EUROPE FROM BOEHRINGER INGELHEIM​

UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again

Nov 9 Hikma Pharmaceuticals Plc is in dispute with the Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's popular lung drug Advair in the U.S, the drugmaker said on Thursday, when trimming 2017 revenue guidance for its generics business for a third time.

Drugmaker Hikma cuts generics sales forecast a third time

Nov 9 Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for a third time.

BRIEF-Hikma Pharmaceuticals says ‍continue to expect FY revenue around $2.0 bln​

* ‍CONTINUE TO EXPECT FULL YEAR REVENUE TO BE AROUND $2.0 BILLION IN CONSTANT CURRENCY IN 2017​

BRIEF-Hikma launches serious infections treatment in the United States

* ‍CAPSULES ARE INDICATED FOR TREATMENT OF SERIOUS INFECTIONS CAUSED BY SUSCEPTIBLE STRAINS OF CANDIDA AND/OR CRYPTOCOCCUS​ Source text for Eikon: Further company coverage:

BRIEF-Hikma says US unit launched pantoprazole sodium for injection

* U.S. unit west-ward pharmaceuticals has launched pantoprazole sodium for injection, 40mg​ Source text for Eikon: Further company coverage:

Drugmaker Hikma's U.S. unit raises medicine prices: Financial Times

NEW YORK Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

NEW YORK, Aug 20 Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400 percent and is charging more for five other medicines as well, the Financial Times reported on Sunday.

Drugmaker Hikma trims sales forecasts, shares fall

Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall

Aug 17 Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low.

Select another date: